SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Weikang Bio-Technology Group Co., Inc. – ‘10-K’ for 12/31/11 – ‘EX-14.1’

On:  Friday, 3/30/12, at 3:12pm ET   ·   For:  12/31/11   ·   Accession #:  1144204-12-18721   ·   File #:  333-165684

Previous ‘10-K’:  ‘10-K/A’ on 12/28/11 for 12/31/10   ·   Latest ‘10-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/12  Weikang Bio-Tech Group Co., Inc.  10-K       12/31/11   44:2.3M                                   Toppan Merrill/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    474K 
 2: EX-10.12    Material Contract                                   HTML     15K 
 3: EX-14.1     Code of Ethics                                      HTML     26K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     14K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     13K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     19K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     19K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     15K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     15K 
28: R1          Document and Entity Information                     HTML     45K 
21: R2          Consolidated Balance Sheets                         HTML    128K 
26: R3          Consolidated Balance Sheets (Parenthetical)         HTML     25K 
30: R4          Consolidated Statements of Income and               HTML     99K 
                Comprehensive Income                                             
41: R5          Consolidated Statements of Cash Flows               HTML    111K 
22: R6          Consolidated Statements of Stockholders' Equity     HTML     64K 
25: R7          Organization and Description of Business            HTML     26K 
20: R8          Summary of Significant Accounting Policies          HTML     65K 
18: R9          Accounts Receivable                                 HTML     22K 
42: R10         Advances to Suppliers and Other Receivables         HTML     17K 
32: R11         Inventory                                           HTML     20K 
31: R12         Property and Equipment, net                         HTML     23K 
36: R13         Construction in Progress                            HTML     15K 
37: R14         Intangible Assets                                   HTML     21K 
35: R15         Related Party Transactions                          HTML     20K 
38: R16         Major Customers and Vendors                         HTML     15K 
27: R17         Unearned Revenue                                    HTML     18K 
29: R18         Taxes Payable                                       HTML     17K 
34: R19         Other Payables and Accrued Expenses                 HTML     18K 
44: R20         Deferred Tax Asset (Liability)                      HTML     19K 
39: R21         Income Taxes                                        HTML     26K 
23: R22         Stockholders' Equity                                HTML     62K 
33: R23         Statutory Reserves                                  HTML     18K 
24: R24         Contingencies                                       HTML     16K 
16: R25         Goodwill                                            HTML     16K 
40: R26         Subsequent Event                                    HTML     16K 
43: XML         IDEA XML File -- Filing Summary                      XML     53K 
19: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    212K 
10: EX-101.INS  XBRL Instance -- wkbt-20111231                       XML    314K 
12: EX-101.CAL  XBRL Calculations -- wkbt-20111231_cal               XML    105K 
13: EX-101.DEF  XBRL Definitions -- wkbt-20111231_def                XML    300K 
14: EX-101.LAB  XBRL Labels -- wkbt-20111231_lab                     XML    341K 
15: EX-101.PRE  XBRL Presentations -- wkbt-20111231_pre              XML    348K 
11: EX-101.SCH  XBRL Schema -- wkbt-20111231                         XSD     60K 
17: ZIP         XBRL Zipped Folder -- 0001144204-12-018721-xbrl      Zip     56K 


‘EX-14.1’   —   Code of Ethics


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 14.1

 

WEIKANG BIO-TECHNOLOGY GROUP CO., INC. CODE OF ETHICS

 

Introduction

 

The Board of Directors of Weikang Bio-technology Group Co., Inc. has adopted this code of ethics (the “Code”), which is applicable to all directors, officers and employees to:

 

Promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; promote the full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the SEC, as well as in other; public communications made by or on behalf of the Company; promote compliance with applicable governmental laws, rules and regulations; deter wrongdoing; and require prompt internal reporting of breaches of, and accountability for adherence to, this Code. This Code may be amended only by resolution of the Company’s Board of Directors. In this Code, references to the “Company” means Weikang Bio-technology Group Inc., and, in appropriate context, the Company’s subsidiaries.

 

Honest, Ethical and Fair Conduct

 

Each person owes a duty to the Company to act with integrity. Integrity requires, among other things, being honest, fair and candid. Deceit, dishonesty and subordination of principle are inconsistent with integrity.

 

Service to the Company never should be subordinated to personal gain and advantage.

 

Each person must:

 

Act with integrity, including being honest and candid while still maintaining the confidentiality of the Company’s information where required or in the Company’s interests;

 

Observe all applicable governmental laws, rules and regulations;

 

Comply with the requirements of applicable accounting and auditing standards, as well as Company policies, in the maintenance of a high standard of accuracy and completeness in the Company’s financial records and other business-related information and data;

 

Adhere to a high standard of business ethics and not seek competitive advantage through unlawful or unethical business practices;

 

Deal fairly with the Company’s customers, suppliers, competitors and employees;

 

 C: 
 
 

 

 

Refrain from taking advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing practice;

 

Protect the assets of the Company and ensure their proper use.;

 

Refrain from taking for themselves personally opportunities that are discovered through the use of corporate assets or using corporate assets, information or position for general personal gain outside the scope of employment with the Company;

 

Avoid conflicts of interest wherever possible;

 

Anything that would be a conflict for a person subject to this Code also will be a conflict if it is related to a member of his or her family or a close relative. Examples of conflict of interest situations include, but are not limited to, the following: any significant ownership interest in any supplier or customer; any consulting or employment relationship with any customer, supplier or competitor; any outside business activity that detracts from an individual’s ability to devote appropriate time and attention to his or her responsibilities with the Company; the receipt of any money, non-nominal gifts or excessive entertainment from any company with which the Company has current or prospective business dealings; being in the position of supervising, reviewing or having any influence on the job evaluation, pay or benefit of any close relative; selling anything to the Company or buying anything from the Company, except on the same terms and conditions as comparable officers or directors are permitted to so purchase or sell; and any other circumstance, event, relationship or situation in which the personal interest of a person subject to this Code interferes, or even appears to interfere with the interests of the Company as a whole.

 

Disclosure

 

The Company strives to ensure that the contents of and the disclosures in the reports and documents that the Company files with the Securities and Exchange Commission (the “SEC”) and other public communications shall be full, fair, accurate, timely and understandable in accordance with applicable disclosure standards, including standards of materiality, where appropriate. Each person must; not knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company, including to the Company’s independent auditors, governmental regulators, self-regulating organizations and other governmental officials, as appropriate; and in relation to his or her area of responsibility, properly review and critically analyze proposed disclosure for accuracy and completeness. In addition to the foregoing, the Chief Executive Officer of Company and each subsidiary of Company, the Chief Financial Officer of Parent and each subsidiary, and each other person that typically is involved in the financial reporting of the Company must familiarize himself or herself with the disclosure requirements applicable to the Company as well as the business and financial operations of the Company. Each person must promptly bring to the attention of the Chairman of the Audit Committee of the Company’s Board of Directors any information he or she may have concerning (a) significant deficiencies in the design or operation of internal and/or disclosure controls which could adversely affect the Company’s ability to record, process, summarize and report financial data or (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s financial reporting, disclosures or internal controls.

 

 C: 
 
 

 

 

Compliance

 

It is the Company’s obligation and policy to comply with all applicable governmental laws, rules and regulations. It is the personal responsibility of each person to, and each person must, adhere to the standards and restrictions imposed by those laws, rules and regulations, including those relating to accounting and auditing matters.

 

Reporting and Accountability

 

The Audit Committee of the Board of Directors of the Company is responsible for applying this Code to specific situations in which questions are presented to it and has the authority to interpret this Code in any particular situation. Any person who becomes aware of any existing or potential breach of this Code is required to notify the Chairman of the Audit Committee promptly. Failure to do so is itself a breach of this Code. Specifically, each person must: Notify the Chairman of the Audit Committee promptly of any existing or potential violation of this Code; Not retaliate against any other person for reports of potential violations that are made in good faith. The Company will follow the following procedures in investigating and enforcing this Code and in reporting on the Code: The Audit Committee will take all appropriate action to investigate any breaches reported to it. If the Audit Committee determines that a breach has occurred, it will inform the Board of Directors. Upon being notified that a breach has occurred, the Board will take or authorize such disciplinary or preventive action as it deems appropriate, after consultation with the Audit Committee and General Counsel, up to and including dismissal or, in the event of criminal or other serious violations of law, notification of the SEC or other appropriate law enforcement authorities. No person following the above procedure shall, as a result of following such procedure, be subject by the Company or any officer or employee thereof to discharge, demotion suspension, threat, harassment or, in any manner, discrimination against such person in terms and conditions of employment.

 

Waivers and Amendments

 

Any waiver (defined below) or an implicit waiver (defined below) from a provision of this Code for the principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions or any amendment (as defined below) to this Code is required to be disclosed in the Company’s Annual Report on Form 10-K or in a Current Report on Form 8-K filed with the SEC. A “waiver” means the approval by the Company’s Board of Directors of a material departure from a provision of the Code. An “implicit waiver” means the Company’s failure to take action within a reasonable period of time regarding a material departure from a provision of the Code that has been made known to an executive officer of the Company. An “amendment” means any amendment to this Code other than minor technical, administrative or other non-substantive amendments hereto. All persons should note that it is not the Company’s intention to grant or to permit waivers from the requirements of this Code. The Company expects full compliance with this Code.

 

 C: 
 
 

 

 

Other Policies and Procedures

 

Any other policy or procedure set out by the Company in writing or made generally known to employees, officers or directors of the Company prior to the date hereof or hereafter are separate requirements and remain in full force and effect.

 

Inquiries

 

All inquiries and questions in relation to this Code or its applicability to particular people or situations should be addressed to the Director of Administration.

 

 C: 
 
 

 

 

Top
Filing Submission 0001144204-12-018721   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 25, 8:18:58.1am ET